Industry demands EC clarification on combi products
This article was originally published in Clinica
The recent European Commission workshop on the scope and potential overlap of the recently revised Directive on the Community Code relating to Medicinal Products For Human Use (2004/27EC) did little to reassure the medical devices industry that products currently regulated as medical devices would not be swept away into the pharma arena.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.